Your browser doesn't support javascript.
loading
A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes.
Gallon, Richard; Mühlegger, Barbara; Wenzel, Sören-Sebastian; Sheth, Harsh; Hayes, Christine; Aretz, Stefan; Dahan, Karin; Foulkes, William; Kratz, Christian P; Ripperger, Tim; Azizi, Amedeo A; Baris Feldman, Hagit; Chong, Anne-Laure; Demirsoy, Ugur; Florkin, Benoît; Imschweiler, Thomas; Januszkiewicz-Lewandowska, Danuta; Lobitz, Stephan; Nathrath, Michaela; Pander, Hans-Jürgen; Perez-Alonso, Vanesa; Perne, Claudia; Ragab, Iman; Rosenbaum, Thorsten; Rueda, Daniel; Seidel, Markus G; Suerink, Manon; Taeubner, Julia; Zimmermann, Stefanie-Yvonne; Zschocke, Johannes; Borthwick, Gillian M; Burn, John; Jackson, Michael S; Santibanez-Koref, Mauro; Wimmer, Katharina.
Afiliación
  • Gallon R; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Mühlegger B; Division of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
  • Wenzel SS; Division of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
  • Sheth H; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Hayes C; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Aretz S; Institute of Human Genetics, Biomedical Centre, University Hospital Bonn, Bonn, Germany.
  • Dahan K; Centre de génétique humaine, Institut de pathologie et génétique (IPG), Gosselies, Belgium.
  • Foulkes W; Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Kratz CP; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Ripperger T; Department of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada.
  • Azizi AA; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
  • Baris Feldman H; Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
  • Chong AL; Department of Human Genetics, Hannover Medical School, Hannover, Germany.
  • Demirsoy U; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Florkin B; The Genetics Institute, Rambam Health Care Campus, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
  • Imschweiler T; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Januszkiewicz-Lewandowska D; Department of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada.
  • Lobitz S; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
  • Nathrath M; Department of Pediatric Oncology, Kocaeli University, Kocaeli, Turkey.
  • Pander HJ; Department of Pediatrics, CHR Citadelle Hospital, University of Liège, Liège, Belgium.
  • Perez-Alonso V; Pediatric Oncology, Helios-Klinikum, Krefeld, Germany.
  • Perne C; Department of Pediatric Oncology, Hematology and Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
  • Ragab I; Department of Pediatric Oncology/Pediatric Hematology, Kliniken der Stadt Köln gGmbH, Children's Hospital Amsterdamer Strasse, Köln, Germany.
  • Rosenbaum T; Pediatric Hematology and Oncology, Klinikum Kassel, Kassel, Germany.
  • Rueda D; Department of Pediatrics, Pediatric Oncology Center , Technische Universität München, Munich, Germany.
  • Seidel MG; Institut für Klinische Genetik, Olgahospital, Stuttgart, Germany.
  • Suerink M; Pediatrics Department, University Hospital Doce de Octubre, i+12 Research Institute, Madrid, Spain.
  • Taeubner J; Institute of Human Genetics, Biomedical Centre, University Hospital Bonn, Bonn, Germany.
  • Zimmermann SY; Pediatrics Department, Hematology-Oncology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Zschocke J; Department of Pediatrics, Sana Kliniken Duisburg, Duisburg, Germany.
  • Borthwick GM; Hereditary Cancer Laboratory, University Hospital Doce de Octubre, i+12 Research Institute, Madrid, Spain.
  • Burn J; Research Unit Pediatric Hematology and Immunology, Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.
  • Jackson MS; Department of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands.
  • Santibanez-Koref M; Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children´s Hospital, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany.
  • Wimmer K; Department of Pediatric Hematology and Oncology, Children's Hospital, University Hospital, Frankfurt, Germany.
Hum Mutat ; 40(5): 649-655, 2019 05.
Article en En | MEDLINE | ID: mdl-30740824
ABSTRACT
Constitutional mismatch repair deficiency (CMMRD) is caused by germline pathogenic variants in both alleles of a mismatch repair gene. Patients have an exceptionally high risk of numerous pediatric malignancies and benefit from surveillance and adjusted treatment. The diversity of its manifestation, and ambiguous genotyping results, particularly from PMS2, can complicate diagnosis and preclude timely patient management. Assessment of low-level microsatellite instability in nonneoplastic tissues can detect CMMRD, but current techniques are laborious or of limited sensitivity. Here, we present a simple, scalable CMMRD diagnostic assay. It uses sequencing and molecular barcodes to detect low-frequency microsatellite variants in peripheral blood leukocytes and classifies samples using variant frequencies. We tested 30 samples from 26 genetically-confirmed CMMRD patients, and samples from 94 controls and 40 Lynch syndrome patients. All samples were correctly classified, except one from a CMMRD patient recovering from aplasia. However, additional samples from this same patient tested positive for CMMRD. The assay also confirmed CMMRD in six suspected patients. The assay is suitable for both rapid CMMRD diagnosis within clinical decision windows and scalable screening of at-risk populations. Its deployment will improve patient care, and better define the prevalence and phenotype of this likely underreported cancer syndrome.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndromes Neoplásicos Hereditarios / Neoplasias Encefálicas / Neoplasias Colorrectales / Predisposición Genética a la Enfermedad / Inestabilidad de Microsatélites / Reparación de la Incompatibilidad de ADN / Estudios de Asociación Genética / Leucocitos Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hum Mutat Asunto de la revista: GENETICA MEDICA Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndromes Neoplásicos Hereditarios / Neoplasias Encefálicas / Neoplasias Colorrectales / Predisposición Genética a la Enfermedad / Inestabilidad de Microsatélites / Reparación de la Incompatibilidad de ADN / Estudios de Asociación Genética / Leucocitos Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hum Mutat Asunto de la revista: GENETICA MEDICA Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido